Sandoz Group AGMEX:SDZN 16 ROA % is 4.81% as of Dec. 2025, which is 16% above its 10-year median of 4.13. GuruFocus rates MEX:SDZN with a GF Score™ of 16/100. The stock has 6 warning signs investors should review. Among 1,006 Drug Manufacturers companies, Sandoz Group AG ranks better than 57.46% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Sandoz Group AG's annualizedNet Income for the quarter that ended in Dec. 2025 was MXN19,338 Mil.
Sandoz Group AG's average Total Assets over the quarter that ended in Dec. 2025 was MXN401,810 Mil. Therefore, Sandoz Group AG's annualized ROA % for the quarter that ended in Dec. 2025 was 4.81%.
The historical rank and industry rank for Sandoz Group AG's ROA % or its related term are showing as below:
MEX:SDZN'
s ROA % Range Over the Past 10 Years
Min: 0.4 Med: 4.13 Max: 4.83
Current: 4.17
During the past 4 years, Sandoz Group AG's highest ROA % was 4.83%. The lowest was 0.40%. And the median was 4.13%.
MEX:SDZN's ROA % is ranked better than 57.46% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 2.685
vs MEX:SDZN: 4.17
Sandoz Group AG (MEX:SDZN) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Sandoz Group AG ROA % Related Terms
Sandoz Group AG ROA % Historical Data
* Premium members only.
The historical data trend for Sandoz Group AG's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sandoz Group AG's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sandoz Group AG ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sandoz Group AG's ROA % distribution charts can be found below:
* The bar in red indicates where Sandoz Group AG's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
Sandoz Group AG (MEX:SDZN) has a ROA % of 4.81% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Sandoz Group AG and its competitors. This is 16% above median its historical median of 4.13. Over the past decade, Sandoz Group AG's ROA % has ranged from 0.40 to 4.83. According to the industry distribution chart, Sandoz Group AG ranks #428 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 42.5%.
Is Sandoz Group AG's ROA % too high?
Sandoz Group AG's current ROA % of 4.81% is 16% above median its 10-year median of 4.13. Over the past 10 years, this metric has ranged from a low of 0.40 to a high of 4.83. The Drug Manufacturers industry median ROA % is 2.69. Sandoz Group AG's value of 4.81% is 79.1% above this industry median. Based on the distribution chart, Sandoz Group AG ranks #428 out of 1006 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Sandoz Group AG has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Sandoz Group AG's ROA % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sandoz Group AG ranks #428 out of 1006 companies for ROA %. This puts Sandoz Group AG in the upper half of its industry. The industry median ROA % is 2.69. Sandoz Group AG's value of 4.81% is 79.1% above this benchmark. Historically, Sandoz Group AG's own ROA % has ranged from 0.40 to 4.83 over the past decade. While the company's 10-year median is 4.13 vs. the industry median of 2.69, Sandoz Group AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.69, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sandoz Group AG's current ROA % of 4.81% is 79.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Sandoz Group AG and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sandoz Group AG's current ROA % is 4.81%, which is 16% above median its own 10-year median of 4.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sandoz Group AG stock overvalued right now?
Sandoz Group AG (MEX:SDZN) has a current ROA % of 4.81%. The current ROA % is 4.81%, which is 16% above median its 10-year median of 4.13 and 79.1% above the Drug Manufacturers industry median of 2.69. Sandoz Group AG's overall GF Score™ is 16/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Sandoz Group AG (MEX:SDZN), the current ROA % is 4.81% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $11 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among the leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006, as well as the first US biosimilar, Zarxio, in 2015. It has over 10 launched biosimilars in a number of markets and over 20 assets in its pipeline.
16GF Score
Get the complete analysis for MEX:SDZN
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:SDZN has been successfully added to your 